HUASPGI@EC2606A(18213.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
HUASPGI@EC2606A
18213.HK
News
View More

Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors

Ascentage Pharma Group International has unveiled its 2026 global innovation strategy, focusing on expanding clinical development and product commercialization in hematologic malignancies and solid tumors. The plan includes advancing its innovative therapy pipeline, progressing multiple global Phase III trials, and developing APG-3288, a next-generation BTK degrader. The company aims to meet unmet clinical needs and enhance its global portfolio of products and clinical programs.

Reuters·
US
AAPG
-0.80%
Reuters·
US
AAPG
-0.80%

Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial

Ascentage Pharma Group International has received FDA IND clearance for its BTK degrader APG-3288, allowing it to initiate a global Phase I trial for patients with relapsed or refractory B-cell malignancies. This development enhances Ascentage's hematology pipeline and targets both wild-type and mutant BTK forms, potentially addressing treatment resistance. Despite a recent analyst rating of 'Buy' with a $50 price target, concerns about high debt and negative profitability have led to a low overall stock score, with some analysts rating it as 'Underperform.'

Tip Ranks·
HK
06855
-1.92%
US
AAPG
-0.80%
Tip Ranks·
HK
06855
-1.92%
US
AAPG
-0.80%

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 | AAPG Stock News

Ascentage Pharma has received IND clearance from the U.S. FDA for its next-generation BTK-targeted protein degrader, APG-3288. This marks a significant expansion of the company's innovative pipeline. The Phase I study will evaluate APG-3288 in patients with relapsed/refractory B-cell malignancies, aiming to address the urgent need for new treatments due to resistance to existing BTK inhibitors. APG-3288 utilizes Ascentage's PROTAC technology to induce degradation of BTK, potentially offering a novel therapeutic strategy in hematologic malignancies.

StockTitan·
US
AAPG
-0.80%
HK
06855
-1.92%
StockTitan·
US
AAPG
-0.80%
HK
06855
-1.92%

Ascentage Pharma Enhances Board Structure, Sets Shareholder Vote on Equity Grant

Ascentage Pharma Group International has enhanced its board structure by appointing Dr. Debra Yu to the nomination committee and naming Dr. David Sidransky as lead independent non-executive director. The company established a dedicated R&D committee for pipeline strategy oversight. A proposed equity grant to substantial shareholder Dr. Zhai Yifan will require independent shareholder approval, with part of her RSU vesting deferred until after the vote. The stock currently holds a Hold rating with a price target of HK$63.00.

Tip Ranks·
US
AAPG
-0.80%
HK
06855
-1.92%
Tip Ranks·
US
AAPG
-0.80%
HK
06855
-1.92%

Ascentage Pharma Sets Out Board Line-Up and Key Committee Roles

Ascentage Pharma Group International has announced its board composition, led by Executive Director and Chairman Dr. Yang Dajun, featuring a mix of directors with expertise in science and industry. The company detailed its governance committees—Audit, Remuneration, Nomination, and R&D—emphasizing oversight and decision-making. The latest analyst rating for its stock (HK:6855) is a Hold with a price target of HK$63.00. Ascentage focuses on innovative drug R&D and is listed on the Hong Kong Stock Exchange under stock code 6855, with a market cap of HK$19.85B.

Tip Ranks·
HK
06855
-1.92%
US
AAPG
-0.80%
Tip Ranks·
HK
06855
-1.92%
US
AAPG
-0.80%
Posts
View More
© 2026 Longbridge｜Disclaimer